|
23.12.2024 07:19:24
|
Sanofi To Expand Collaboration With SK Bioscience For Next-generation Pneumococcal Vaccines
(RTTNews) - Sanofi (SNYNF, SNY) and SK bioscience have entered an expanded agreement to develop, license and commercialize next-generation pneumococcal vaccines for both pediatric and adult populations. The expansion builds on the existing collaboration to develop and commercialize a PCV21 pediatric vaccine, for which the phase 3 program commenced last week.
Under the terms of the expanded agreement, the companies will co-fund research and development costs. Sanofi will pay 50 million eurs upfront to SK bioscience, followed by development and commercial milestone payments. Once registered, Sanofi will commercialize the vaccines worldwide except for South Korea, where SK bioscience will have commercial exclusivity. SK bioscience will receive royalty payments on product sales outside South Korea.
For More Such Health News, visit rttnews.com.
Nachrichten zu Sanofi S.A. (spons. ADRs)
Analysen zu Sanofi S.A. (spons. ADRs)
Im BX Morningcall werden folgende Aktien analysiert und erklärt:
NEU✅ Meta Platforms
NEU✅ Microsoft
inklusive Rebalancing:
❌ Arthur J. Gallagher & Co
❌ Progressive
👉🏽 https://bxplus.ch/bx-musterportfolio/
Inside Trading & Investment
Mini-Futures auf SMI
Aktien in diesem Artikel
| Sanofi S.A. (spons. ADRs) | 53.50 | 0.28% |
|
| Sanofi S.A. | 98.43 | 5.07% |
|
Meistgelesene Nachrichten
Top-Rankings
Börse aktuell - Live Ticker
SMI fester -- DAX wenig bewegt -- Börsen in Fernost letztlich uneinig - Nikkei stabilWährend sich der heimische Aktienmarkt fester zeigt, kommt der deutsche Leitindex zur Wochenmitte nicht vom Fleck. Auch die asiatischen Indizes gaben indes überwiegend nach, lediglich der Nikkei hielt sich knapp im Plus.
finanzen.net News
| Datum | Titel |
|---|---|
|
{{ARTIKEL.NEWS.HEAD.DATUM | date : "HH:mm" }}
|
{{ARTIKEL.NEWS.BODY.TITEL}} |